Compare Heron Therapeutics Inc (HRTX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Verisign, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Verisign, Inc. trades at $283.36 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 423× Heron Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | VRSN | |
|---|---|---|
Market Cap | $61.47M | $26.00B |
Sector | Health | Technology |
52-Week High | $1.49 | $310.00 |
52-Week Low | $0.32 | $211.49 |
Enterprise Value | $168.21M | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
VeriSign (VRSN) trades at $293.34, down 0.41% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with record domain registrations and 6% revenue growth, maintaining robust profit margins near 50%. Recent delegation of .web domain and AI-driven registration growth provide positive catalysts.
The stock offers 9% upside to consensus price target of $320 with 60% analyst buy ratings. Key risks include contract renewals and premium valuation at 31x P/E. Strong cash flow generation and dividend payments support shareholder returns amid stable internet infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
